Progress in platelet blockers: The target is the P2Y12 receptor

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 27, Issue 3, 2013, Pages 620-624

  Patel, Prakash A ^a   Lane, Bernard ^a   Augoustides, John G T ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

adenosine diphosphate; bleeding; cangrelor; cardiac surgery; clopidogrel; clopidogrel resistance; coronary stent; elinogrel; guidelines; hepatic metabolism; noncardiac surgery; P2Y12 receptor; percutaneous coronary intervention; perioperative period; platelets; prasugrel; thienopyridines; thrombosis; ticagrelor; ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; ELINOGREL; EPTIFIBATIDE; HIRULOG; PRASUGREL; PROSTACYCLIN; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR; TIROFIBAN;

ACUTE CORONARY SYNDROME; ACUTE LUNG INJURY; ANTICOAGULANT THERAPY; CARDIOVASCULAR MORTALITY; CREATININE BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DYSPNEA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; META ANALYSIS (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; URIC ACID BLOOD LEVEL;

ADENOSINE; ADENOSINE MONOPHOSPHATE; HUMANS; PERIOPERATIVE CARE; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; QUINAZOLINONES; RECEPTORS, PURINERGIC P2Y12; SULFONAMIDES; THIOPHENES;

EID: 84877730424     PISSN: 10530770     EISSN: 15328422     Source Type: Journal    
DOI: 10.1053/j.jvca.2013.01.008     Document Type: Review

References (66)

1. 12 inhibitors Circulation 121 2010 171 179
2. F. Mohelmani, and D.E. Jackson P2Y(12) receptor: Platelet thrombus formation and medical interventions Int J Hematol 2012 [Epub ahead of print]
3. X. Ji, and M. Hou Novel agents for antiplatelet therapy J Hematol Oncol 4 2011 4 44
4. R.F. Power, B.G. Hynes, and D. Moran Modern antiplatelet agents in coronary artery disease Expert Rev Cardiovasc Ther 10 2012 1261 1272
5. 12 inhibitors in the treatment of acute coronary syndrome Cardiovasc Ther 30 2012 167 173
6. 12 antagonists as inhibitors of platelet function Thromb Haemost 105 2011 96 106
7. J. van der Linden Pro: Continuation of aspirin/clopidogrel for cardiac surgery J Cardiothorac Vasc Anesth 21 2007 602 605
8. P.A. Patel, and J.G. Augoustides Progress in platelet medicine: Focus on stent thrombosis and drug resistance J Cardiothorac Vasc Anesth 24 2010 722 727
9. J.D. Snoep, M.M. Hovens, and J.C. Eikenboom Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis Am Heart J 154 2007 221 231
10. A. Kastrati New antiplatelet agents: The end of resistance? Thromb Res 130 suppl 1 2012 S53 S55
11. V.A. Ferraris, S.P. Saha, and J.H. Oestreich 2012 Update to the Society of Thoracic Surgeons guideline on the use of antiplatelet drugs in patients having cardiac and noncardiac operations Ann Thorac Surg 94 2012 1761 1781
12. A.H. Menkis, J. Martin, and D.C. Cheng Drugs, devices, technologies and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: A consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011 Innovations (Philadelphia) 7 2012 229 241
13. S. Lavi, and R. Lavi Perioperative management of antiplatelet agents in patients undergoing cardiac surgery J Cardiothorac Vasc Anesth 26 2012 680 686
14. B.P. Nalla, J. Freedman, and G.M.T. Hare Update on blood conservation for cardiac surgery J Cardiothorac Vasc Anesth 26 2012 117 133
15. K.A. Tanaka, D. Bolliger, and R. Vadlamudi Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma J Cardiothorac Vasc Anesth 26 2012 1083 1093
16. J.P. Collet, T. Cuisset, and G. Range Bedside monitoring to adjust antiplatelet therapy for coronary stenting N Engl J Med 367 2012 2100 2109
17. N.A. Farid, C.D. Payne, and D.S. Small Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently Clin Pharmacol Ther 81 2007 735 741
18. G. Sardella, S. Calcagno, and M. Mancone Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high dose clopidogrel versus prasugrel: The RESET GENE trial Circ Cardiovasc Intervent 5 2012 698 704
19. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic and clinical outcomes Circulation 119 2009 2553 2560
20. S.D. Wiviott, E. Braunwald, and C.H McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
21. A.C. Salisbury, K. Wang, and D.J. Cohen Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: Weighing the benefits and risks of prasugrel versus clopidogrel Circ Cardiovasc Qual Outcomes 2012 [Epub ahead of print]
22. 12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease Eur Heart J 29 2008 21 30
23. 12 inhibitor Expert Opin Pharmacother 2012 [Epub ahead of print]
24. P.A. Gurbel, K.P. Bliden, and K. Butler Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: The ONSET/OFFSET study Circulation 120 2009 2577 2585
25. 12 inhibitors Semin Thromb Hemost 31 2005 195 204
26. 12 receptor antagonist Ann Pharmacother 44 2010 524 537
27. J.J. van Giezen, L. Nilsson, and P. Bernsston Ticagrelor binds to the human P2Y receptor independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation J Thromb Haemost 7 2009 1556 1565
28. R. Teng, J. Maya, and K. Butler Evaluation of the pharmacokinetics and pharmacodynamics of ticagrelor with aspirin in healthy volunteers Platelets 2012 [Epub ahead of print]
29. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
30. 12 inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention - Systematic review and meta-analysis Thromb Haemost 2012 [Epub ahead of print]
31. J.J. Dinicotantonio, and V.L. Serebruany Comparing ticagrelor versus clopidogrel in patients with a history of cerebrovascular disease: A net clinical harm Stroke 43 2012 3409 3410
32. F.W. Verheugt Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke Circulation 125 2012 2821 2823
33. S.K. James, R.F. Storey, and N.S. Khurmi Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack Circulation 125 2012 2914 2921
34. P. Kohli, L. Wallentin, and F. Reves Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study Circulation 2012 [Epub ahead of print]
35. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST elevation myocardial infarction. Circ Cardiovasc Intervent [Epub ahead of print]
36. D. Alexopoulos, A. Galati, and I. Xanthopoulou Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention J Am Coll Cardiol 60 2012 193 199
37. D.W. Park, J.M. Ahn, and H.G. Song Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention Am Heart J 165 2013 34 42
38. 12 antagonist Coron Artery Dis 23 2012 368 374
39. 12 inhibitors Thromb Haemost 105 suppl 1 2011 75 81
40. D.L. Bhatt, A.M. Linoff, and C.M. Gibson Intravenous platelet blockade with cangrelor during PCI N Engl J Med 361 2009 2330 2341
41. R.A. Harrington, G.W. Stone, and S. McNulty Platelet inhibition with cangrelor in patients undergoing PCI N Engl J Med 361 2009 2318 2329
42. A. Kastrati, and G. Ndrepepa Cangrelor - A champion lost in translation N Engl J Med 361 2009 2382 2384
43. D.J. Angiolillo, M.S. Firstenberg, and M.J. Price Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery JAMA 307 2012 265 274
44. Y. Hiramatsu, N. Gikakis, and H.L. Anderson Tirofiban provides platelet anesthesia during cardiopulmonary bypass in baboons J Thorac Cardiovasc Surg 113 1997 182 193
45. A. Straub, D. Schiebold, and H.P. Wendel Platelet anesthesia during extracorporeal circulation: Differential effects of GP IIb/IIIa blockers on platelet activation marker P-selectin expression at hypothermia Thromb Res 122 2008 383 389
46. 12 blockade to reduce platelet dysfunction and coagulopathy during experimental extracorporeal circulation and hypothermia Br J Anaesth 108 2012 912 921
47. T. Antoniou, E.I. Kapetanakis, and K. Theodoraki Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost Heart Surg Forum 5 2002 354 357
48. G.M. Palatianos, C.N. Foroulis, and M.I. Vassili Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost J Thorac Cardiovasc Surg 127 2004 548 554
49. A. Koster, M. Kukucka, and F. Bach Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban Anesthesiology 94 2001 245 251
50. J.G. Augoustides Update in hematology: Heparin-induced thrombocytopenia and bivalirudin J Cardiothorac Vasc Anesth 25 2011 371 375
51. H.D. White, D.P. Chew, and H.L. Daueman Reduced immediate ischemic events with cangrelor in PCI: A pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction Am Heart J 163 2012 182 190
52. S. Leonardi, K.W. Mahaffey, and H.D. White Rationale and design of the cangrelor versus standard therapy to achieve optimal management of platelet inhibition PHOENIX trial Am Heart J 163 2012 768 776
53. K.A. Muller, and T. Geister Novel antiplatelet therapy in acute coronary syndromes: What is new in the pipeline? Curr Vasc Pharmacol 10 2012 606 618
54. 12 receptor antagonist for the treatment of acute coronary syndrome and prevention of secondary thrombotic events Curr Opin Invest Drugs 11 2010 340 348
55. 12-recptor inhibitor, versus clopidogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention patients (INNOVATE-PCI) Am Heart J 160 2010 65 72
56. 12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: The INNOVATE - PCI trial Circ Cardiovasc Intervent 5 2012 336 346
57. D.J. Angiolillo, R.C. Welsh, and D. Trenk Pharmacokinetic and pharmacodynamic effects of elinogrel: Results of the platelet function substudy from the intravenous and oral administration of elinogrel to evaluate tolerability and efficacy in nonurgent percutaneous coronary intervention (INNOVATE-PCI) trial Circ Cardiovasc Intervent 5 2012 347 356
58. 12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: The early rapid reversal of platelet thrombosis with intravenous elinogrel before PCI to optimize perfusion reperfusion in acute myocardial infarction (ERASE-MI) pilot trial Am Heart J 158 2009 998 1004
59. 12 inhibition: Still an unmet medical need Circ Cardiovasc Intervent 5 2012 328 331
60. V.L. Serebruany Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel Thromb Haemost 108 2012 1024 1027
61. J.J. Nawarskas, and S.M. Clark Ticagrelor: A novel reversible oral antiplatelet agent Cardiol Rev 19 2011 95 100
62. M. Cattneo, and F.M. Faioni Why does ticagrelor cause dyspnea? Thromb Haemost 108 2012 1031 1036
63. J.G. Augoustides Perioperative thrombotic risk of coronary artery stents: Possible role for intravenous platelet blockade Anesthesiology 107 2007 516
64. P.H. Huang, K.J. Croce, and D.L. Bhatt Recommendations for management of antiplatelet therapy in patients undergoing elective noncardiac surgery after coronary stent implantation Crit Pathw Cardiol 11 2012 177 185
65. F.S. Serwin Is it time to re-evaluate the routines about stopping/keeping platelet inhibitors in conjunction to ambulatory surgery? Curr Opin Anaesthesiol 23 2010 691 696
66. R. Hall, and C.D. Mazer Antiplatelet drugs: A review of their pharmacology and management in the perioperative period Anesth Analg 112 2011 292 318